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Abstract Heat shock factor 1 (HSF1) has long been
recognized as the master transcription factor that regulates
heat shock proteins (HSPs). More recently HSF1 has been
associated with a broader role in regulating response to a
variety of cellular stresses beyond heat-shock. We previ-
ously found that high HSF1 expression is associated with
poor outcome in lung, breast and colon cancers. Impor-
tantly, however, the HSF1 signature correlated with poor
outcome in these studies was not related to the heat shock
response, which suggested that tumor outcome associated
with high HSF expression may be due to processes other
than stress response. Hence, we explored the question
whether high HSF1 expression might be associated with
the cancer stem cell (CSC) phenotype. To do so, we
examined the association of HSF1 with CSC phenotype by
FACS and immunofluorescence. In addition, we evaluated
the effects of HSF1 over-expression and knock-down on
sphere formation and CSC marker expression in breast
cancer cell lines. Here, we report results demonstrating that
high HSF1 not only correlates with CSC marker expres-
sion, but inducible HSF1 over-expression augments and
HSF1 knock-down inhibits CSC phenotype. Furthermore,
HSF1 expression confers resistance to chemotherapeutic
drugs and increases CSC frequency. In conclusion, our
study indicates that one of the potential HSP-independent
HSF1 driven mechanisms that may contribute to poor
outcome in human tumors involves regulation of the CSC
phenotype. Hence, therapeutic inhibition of HSF1 may be
one route to target CSCs in human tumors.
Keywords Breast cancer  Heat shock factor 1 (HSF1) 
Cancer stem cell  Tumorsphere assay
Introduction
Cancer stem cells (CSCs) are subpopulation of tumor cells
that are capable of self-renewal and differentiation [1–4].
CSCs have the ability to initiate tumors with extremely low
seeding numbers in immunocompromised mice and dif-
ferentiate asymmetrically into non-CSCs while maintain-
ing a pool of CSCs. It is thought that CSCs may be resistant
to chemotherapy and radiation due to their low rate of cell
division [5].
While the presence of CSCs has been documented in
multiple human tumors, the mechanisms that regulate CSCs
remain to be fully elucidated. Several pathways including
Hedgehog, NOTCH, andWnt/b-catenin signaling have been
associated with the CSC phenotype [6–8]. However, the rare
nature of CSCs coupled with the methodological challenges
associated with isolating, maintaining, and expanding them
in vitro has slowed progress. Hence, much remains to be
learned about CSC biology.
Heat shock factor 1 (HSF1) is the master transcription
regulator of heat shock response (HSR). In addition, HSF1
coordinates the response of cells to diverse arrays of
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environmental and physiological stresses, such as ischemic
injury, heavy metals, chemicals, free-radicals, inflammation,
etc. [9].
We recently demonstrated that HSF1 is highly expressed
in multiple human tumors including lung, colon, breast, and
ovarian cancers. Importantly, these studies showed that
HSF1 over-expression is associated with significantly worse
outcome in these tumors [10, 11]. Through genome-wide
ChIP-Seq analysis, we also discovered that HSF1 regulates
two classes of genes in tumor cells; one set of genes included
well-known stress response related targets such as HSPs;
however, a second set of genes were involved with various
other cellular processes, including cell cycle, signaling,
metabolism, adhesion, and protein translation [11]. Some-
what surprisingly, it was the non-heat shock HSF1 target
genes that were closely associated with the more aggressive
tumor phenotype, poor outcome, metastasis, and death in
breast, colon, and lung tumors isolated directly from patients
[11]. High HSF1 expression has also been associated with
poor outcome, advanced stage or metastasis in endometrial
Carcinoma, hepatocellular carcinoma, melanoma, and
squamous cell carcinoma [12–15].
In the present study, we provide evidence that the heat
shock-independent activation of HSF1 augments the breast
cancer stem cell phenotype. These results provide a new
mechanism for the association between high HSF1
expression and poor outcome observed in human tumors.
Materials and methods
Cell culture
BPLER and HMLER cells were described previously [16]
and obtained from live tumor culture core (LTCC, http://
sylvester.org/shared-resources/Live-Tumor-Culture-Core).
In brief, the BPLER cells are cultured in BMI-T medium
obtained from LTCC, and HMLER cells are cultured in
MEGM medium (Lonza, Cat. No. CC-3150). The numbers
subsequent to the cell name (i.e., 2, 3, and 4) indicate cell
lines established from different patient donors. SUM159 and
SUM190 were kindly provided by Dr. Stephen Ethier and
cultured in their recommended media (Ham’s F12 contains
5 % fetal bovine serum, 5 lg/ml insulin, and 1 lg/ml
hydrocortisone). All other cell lines were obtained from the
American Type Culture Collection (ATCC) and cultured in
recommended conditions. All the cell lineswere validated by
STR analysis and tested negative for mycoplasma.
Real-time RT-PCR
Quantitative real-time RT-PCR was performed using
SuperScript III First-Strand Synthesis kit and SsoFast TM
EvaGreen Supermix according to the manufacturers’
instructions and analyzed with BioRad CFX Manager
Software. GAPDH mRNA was used as an internal control
to normalize RNA inputs, and expression levels were cal-
culated according to the relative DCt method. Primers
sequences are annotated in Supplemental Table 1.
Flow cytometry and cell sorting
Cells were harvested at 80 % confluence with non-enzy-
matic dissociation buffer (Life Technologies, Cat. No.
13151-014) and cell pellets were washed, resuspended in
Hank’s Balanced Salt Solution (HBSS) buffer containing
0.2 % BSA, and stained with fluorophore-conjugated
monoclonal antibodies per manufacture’s instruction.
Antibodies used for cell sorting included anti-CD44, APC
conjugated (BD Pharmingen, 559942) and CD166, PE
conjugated (BD Pharmingen, 559263). Flow sorting was
performed using BD FACS Aria II and purity of sorted
cells was confirmed to be between 90-95 %. Sorted cells
were washed once with HBSS before protein extraction.
Immunoflurescence staining
Cells were plated on 8-chamber slides, fixed with 4 % PFA
for 15 min at room temperature, and then permeabilized
for 10 min with 0.2 % Tween-20. After blocking for 1 h in
10 % Goat serum, slides were incubated overnight with
primary antibodies at 4 C, followed by 45 min incubation
with Alexa Fluorophore-labeled secondary antibodies.
Fluoro-Gel II containing DAPI (Electron Microscopy Sci-
ences, Cat. No. 17985-50) was used to mount slides, and
images were taken on an EVOS fluorescence microscope
(AMG & Life Tech). Primary antibodies and their dilutions
used in our experiments are listed in Supplemental Table 2.
Doxycycline inducible HSF1 over-expression
and knockdown
For inducible HSF1 over-expression, a complete HSF1
ORF was subcloned into pENTR1A gateway entry vector
(ENTR) and transferred into pLenti CMV/TO Hygro DEST
plasmid (Addgene, 17291) provided by Dr. Eric Campeau
[17]. pLenti CMV TetR Blast was used for Tet-repressor
expression (Addgene 17492). For inducible HSF1 knock-
down, specific HSF1 shRNA sequences were obtained
from Dr. Susan Lindquist [11] and cloned into pLKO-Tet-
On-Neo plasmid provided by Dr. Dmitri Wiederschain
from Addgene (Cat. No. 21916) [18]. Non-target shRNA
(NT shRNA) was cloned into the same plasmid to serve as
a control. Lentiviral packaging was achieved using the
second generation packaging plasmid pCMV-dR8.2 dvpr
and pCMV-VSV-G (Addgene Cat. No. 8455 and 8454).
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Lentivirus-infected cells were selected with antibiotic
treatment. Doxycycline (DOX) was added into cell culture
to induce HSF1 over-expression or knockdown before
experiments. To ensure that the experiments were carried
out below toxic DOX doses, first serial dilutions of DOX
were tested and 1 ng/ml was determined to be optimal for
use in HSF1 over-expression or knockdown.
Tumorsphere formation
Tumorsphere formation assays were performed following
Clarke et al. with slight modification [19]. In brief, 3000 to
5000 cells were plated on 6-well plates pretreated with
polyhema and maintained in 4-ml tumorsphere media. The
tumorsphere medium is composed of a 1:1 ratio of DMEM/
F12 containing 2 % B27 (Invitrogen), 20 ng/ml EGF,
20 ng/ml bFGF (BD Biosciences), 4 lg/ml heparin
(Sigma), and 0.5 % methyl cellulose. For inducible HSF1
over-expression or knockdown groups, cells were pre-
treated with DOX for 48 h before sphere assay and sphere
medium was supplemented with DOX to maintain the
induction. After 10–14 days of incubation, spheres were
consolidated into a 96-well plate and imaged on an EVOS
fluorescence microscope (AMG & Life Tech) after DAPI
staining and they were also counted using GelCountTM
(Oxford Optronix) following iodonitratetrazolium chloride
staining. Each group included triplicate samples and at
least 3 independent experiments were carried out.
Western blotting
Western blot assays were performed as described before
[20]. Protein lysates were harvested with RIPA buffer and
run on SDS-PAGE gels. Blots were probed with antibodies
listed in Table S2. Blots were developed using SuperSignal
West regular or Dura ECL (ThermoScientific).
Drug treatments
The effect of paclitaxel (Taxol) on cell proliferation was
tested both in 2D and 3D cultures. For 2D culture, cells
were treated with Taxol at 2.5 nM with HSF1 over-ex-
pression or knockdown for 4 days and counted with Trypan
blue exclusion method using a Nexcelom Auto T4 Cel-
lometer. For 3D culture, 5 nM taxol was added into pre-
induced HSF1 over-expression or knockdown cells and
maintained for 4 days. Cells were allowed to recover for
3 days before trypsinization and subjected to tumorsphere
assay. Percentage inhibition on 2D or 3D cell culture was
compared to control groups which only had vehicle
addition.
For protein translation inhibition, 3 pairs of HMLER and
BPLER cells were plated at 8000 cell/well on 96-well plate
one day before adding protein translation inhibitors includ-
ing anisomycin and cycloheximide. Protein translation
inhibitor drugs were removed after 8 h incubation and cells
were maintained in fresh drug-free media for additional four
days before being subjected to CellTiter-Blue (Promega,
Cat. No. G8081) assay. Inhibition of cell proliferation inhi-
bition was compared to the vehicle control group.
Statistical analysis
Inhibition of cell proliferation and sphere formation was
analyzed using student’s t test or one-way ANOVA with
significance at p\ 0.05.
Results
HSF1 is highly expressed in CSCs
We initially explored the potential role of HSF1 in CSCs
using CSC-like BPLER and non-CSC-like HMLER cell
lines. Both BPLER and HMLER lines do form mouse
xenograft tumors that are histologically similar to human
primary triple-negative breast carcinoma (TNBC), and
their global mRNA profile mimics human TNBC [21]. We
previously demonstrated that only the BPLER cells pos-
sessed CSC-like features, even though the matched
HMLER cell lines are isolated from the same patient and
transformed with identical oncogenes [16, 20]. In vivo
tumor formation studies showed that as low as ten unsorted
BPLER cells could form tumors in mice. In contrast,[104
HMLER cells were required for tumor formation. Consis-
tent with these observations, we now show that BPLER
cells express high levels of CSC-associated markers such
as CD326 (EpCAM), CD44v, and CD166 and form five-
fold more tumor spheres compared to HMLER (Fig. 1a)
[22].
Taking the advantage of this cell model system, we
compared HSF1 expression between BPLER and HMLER
cells using real-time PCR and Western blotting, and found
that HSF1 is over-expressed in all three CSC-like BPLER
cell lines compared to non-CSC-like HMLERs not only at
mRNA level (Supplemental Figure 1), but also at protein
level (Fig. 1a), which was the first indication that high
HSF1 levels may be associated with the CSC phenotype.
Next, we confirmed these observations in other cancer
cell lines that represent all three subtypes of breast cancers,
including T47D (ER?), MCF7 (ER?), BT20 (TNBC),
BT474 (Her2?), and HCC1954 (Her2?). Fluorescence-
activated cell sorting (FACS) has been used to isolate CSC
and non-CSC subpopulations based on cell surface marker
expression [23–28]. In our work, we used CD44/CD166
double staining and found that CD44high/CD166high
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subpopulation has significantly greater sphere-forming
capacity compared to non-CSC (CD44low/CD166low)
counterparts (data not shown). By Western blot, we found
that HSF1 expression is much higher in these FACS-en-
riched CSC subpopulations compared to the non-CSCs in
all three subtypes of breast cancer cell lines, further sup-
porting a potential correlation between HSF1 expression
and CSCs phenotype (Fig. 1b).
In order to exclude artifacts associated with FACS
enrichment of CSCs, we used dual-immunofluorescence (IF)
staining to examine co-expression ofHSF1 andCSCmarkers
in situ. These IF stains demonstrate that HSF1 is highly
expressed in 13–35 % of the cells (HSF1high) in all of the
breast cancer cell lines we examined (Fig. 1c, Supplemental
Table 3). Importantly, this HSF1high subpopulation co-ex-
press higher levels of CSC markers (CD44/CD326)
(Fig. 1c). In MDA-MB231 (TNBC) cell line,*35 % cells
express high levels ofHSF1 and 90 %of theseHSF1high cells
co-express CD44. In MCF7 (ER?) cell line, 57 % of the
HSF1high cells are CD44 high. In T47D (ER?) and BT474
(Her2?), approximately 56–68 % of the HSF1high cells are
also CD326 high (Fig. 1c, Supplemental Table 3).
Fig. 1 High HSF1 expression is associated with CSCs in multiple
cell lines. a HSF1 is highly expressed in CSC-like BPLER cells that
express CSC-associated markers CD326, high-molecular weight
CD44v, and CD166 compared to isogenic non-CSC-like HMLER
cells with low CSC marker expression. Western blot of three matched
pairs (#2, 3, and 4) of HMLER and BPLER cell lines was performed
with antibodies against HSF1, CD326, CD44, and CD166. b-actin
(Actin) was used as loading control. CD44H: CD44 standard form.
b HSF1 is highly expressed in FACS-enriched CD44high/CD166high
CSC population (?/?) compared to CD44low/CD166low non-CSC
population (-/-) in multiple breast cancer cell lines; MCF7, T47D,
BT20, BT474, and HCC1954. Western blot of protein lysates were
performed with anti-HSF1 and CD44 antibodies, b-actin (Actin) was
used as loading control. c Double immunofluorescence demonstrates
that HSF1 and CSC markers are co-expressed in the same subpop-
ulation of cells in situ in multiple breast cancer cell lines; MCF7,
MDAMB231, BT474, and T47D. The cells were plated in 8-chamber
slides and simultaneously probed with HSF1 (green) and CSC
antibodies CD44 or CD326 (red), and overlaid with nuclear DAPI
stain (blue) and images were captured with an EVOS fluorescence
microscope at 20X magnification
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HSF1 is necessary to maintain CSC phenotype
in breast cancer cell lines
Given the promising correlation between high HSF1
expression and CSC marker expression, we sought to
determine whether HSF1 plays a functional role in CSC
regulation. After examining endogenous HSF1 expression
levels in twenty-two commonly used breast cancer cell
lines, we selected T47D, MCF7, and BT474 cell lines that
have high endogenous HSF1 expression levels to examine
the changes in CSC phenotype after HSF1 knockdown
(Supplemental Fig. 2).
We used the Tet All-in-One inducible lentiviral shRNA
knockdown system (Tet-on shHSF1) with non-Target
shRNA (NT-shRNA) as control for HSF1 knockdown. The
induction efficiency was tested using various doses of DOX
and as low as 1 ng/ml was able to achieve HSF1 knock-
down (Supplemental Fig. 3). HSF1 expression was reduced
after induction of HSF1-shRNA with 1 ng/ml DOX for
48 h (Fig. 2a), which is associated with a decrease in CSC
Fig. 2 HSF1 is sufficient and necessary to augment CSC phenotype
in multiple cell lines. a HSF1 knockdown decreases CSC-associated
marker expression in breast cancer cell lines BT474, T47D, and
MCF7. HSF1 knockdown was carried out by adding doxycycline
(DOX) at 1 ng/ml for 48 h. The same cell line without DOX addition
served as controls. Western blot of protein lysates (30 ug) from HSF1
knockdown (KD) and control cells was performed with HSF1,
CD326, CD133, CD166, and Nanog antibodies. b-actin (Actin) was
used as loading control. b HSF1 knockdown decreases tumorsphere
formation in breast cancer cell lines BT474, T47D, and MCF7. The
cells were seeded at 3–5 9 103 cells/well on 6-well low adherent
plates, and HSF1 knockdown (KD) was induced by adding DOX
2 days before sphere assay. The same cell line without DOX addition
was used as the control (ctrl). The images provide representative
examples of spheres that were counted after 10–14 days of incubation
under an IF microscope at 29 magnification after DAPI staining
using ImageJ. The bar graphs show the average of 3 replicates
comparing the tumorsphere formation efficiency (TFE) between
HSF1 KD and control. The error bars show standard deviation of the
mean of 3 replicates, student t-test (p\ 0.05). c HSF1 over-
expression increases cancer stem cell (CSC) marker expression in
SUM159 and BT20. HSF1 over-expression was carried out by adding
doxycycline (DOX) at 1 ng/ml for 48 h. The same cell line without
DOX addition was served as control. Western blot of protein lysates
(30 ug) from HSF1 over-expression (HSF1) and control cells (Ctrl)
was performed with HSF1, Sox2, ALDH1 antibodies. b-actin (Actin)
was used as loading control. d HSF1 over-expression increases
tumorsphere formation in breast cancer cell lines SUM159 and BT20.
The images provided is a representative example of spheres that were
counted after 10–14 days under an IF microscope after DAPI staining
using ImageJ. The bar graphs show the average of 3 replicates
comparing the tumorsphere formation efficiency (TFE) between
HSF1 over-expression (HSF1) and control (Ctrl). The error bars
show standard deviation of the mean of 3 replicates, student t-test
(p\ 0.05)
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markers CD133/CD326 in MCF7 and BT474, and CD133/
CD166/Nanog in T47D [22] (Fig. 2a). Moreover, we found
that knockdown of HSF1 significantly decreases 3D
tumorsphere formation (Fig. 2b). In control experiments,
there was no change in the HSF1 levels, CSC markers, or
sphere formation with NT-shRNA cells after DOX stimu-
lation, ensuring the results are specific to HSF1 knockdown
(Supplemental Figure 4). There was also no effects on cell
viability or proliferation rate in 2D cultures after HSF1
knockdown (data not shown), suggesting that the decrease
in sphere formation is not due to a generic suppression of
cell proliferation.
In order to examine the CSC phenotype after HSF1 over-
expression, we selected SUM159 and BT20 because of rela-
tively lower expression levels in these lines (Supplemental
Fig. 2). The HSF1 over-expression in these two cell lines was
achieved using lentiviral tetracycline inducible expression
system (TetR-HSF1). The sphere formation assays revealed
that HSF1 over-expression significantly increases the CSC
markers ALDH1 and SOX2 in both cell lines compared to
control group (Ctrl) (Fig. 2c), and induced the number of
tumorspheres by[twofold (p\ 0.05) (Fig. 2d). This effect
was not due to a generic increase in cell proliferation since we
did not observe any changes in cell proliferation in routine 2D
culture after HSF1 over-expression (data not shown). Taken
together, these data suggest that HSF1 is both sufficient and
necessary to augment the CSC phenotype.
HSF1 expression confers drug resistance
Another feature of CSCs is their relative resistance to
chemotherapy [29]. To test whether HSF1 is involved with
chemo-resistance, we treated cells with HSF1 over-ex-
pression or knockdown with paclitaxel (taxol) and found
that HSF1 overexpressing cells are more resistant to taxol
treatment compared to control both in BT20 and SUM159
cell lines (Fig. 3a). Conversely, HSF1 knockdown mark-
edly increased cell death after taxol treatment in all three
lines tested (BT474, T47D, and MCF7) (Fig. 3b).
In order to test whether changes in chemotherapy
resistance after HSF1 over-expression and knockdown is
related to the CSC phenotype, we carried out 3D tumor-
sphere assays and found that HSF1 over-expression
increases sphere formation in SUM159 after taxol treat-
ment (Taxol ? HSF1) compared to the taxol alone group
(Taxol?) (Fig. 3c). Conversely, in BT474 HSF1 knock-
down cells treated with taxol (Taxol ? HSF1 KD), there
was a small yet statistically significant decrease in number
of tumorspheres compared to treatment alone group
(Taxol?) (Fig. 3d, insets) [9, 30]. Consistent with our
results, Vydra et al. also showed that HSF1 over-expression
causes chemo-resistance by increasing side-population
(SP) cells in human melanoma [31].
Regulation of CSC phenotype by HSF1
To examine the possible factors that may mediate the
actions of HSF1 that effect CSC phenotype, we first ana-
lyzed the expression of heat shock proteins in HSF1high
CSC-like BPLERs and HSFlow non-CSC-like HMLERs.
Compared to the significant differential expression of
HSF1 between BPLERs and HMLERs, we only observed
very minor changes in the expression of HSP70 and
HSP90, two of the main heat shock proteins (Fig. 4a). Next
we examined whether HSF1 over-expression increases
markers of epithelial-to-mesenchymal transition (EMT),
which has been implicated in inducing the CSC phenotype
[10]. However, we did not observe any change in EMT
markers such as E-cadherin, Vimentin, or ZEB1 with HSF1
over-expression or knockdown (Fig. 4b, c). Likewise, there
was no significant change in HSP70 or HSP90 expression
after HSF1 knockdown or over-expression in breast cancer
cells (Fig. 4c).
It has been reported that malignant cells upregulate their
protein translation to manage the high metabolic stress
associated with the malignant phenotype [11]. Santagata
et al. found that the increased protein translation in cancer
cells may be mediated by HSF1 and it is essential for
cancer cell survival [32]. Consistent with this, we found
that both knockdown of HSF1 and inhibition of protein
translation using Cycloheximide or Anisomycin cause
inhibition of HSF1high-CSC-like BPLER proliferation
compared to HSF1low non-CSC-like HMLER cell lines
(Fig. 4d, Supplemental Figure 5).
Discussion
Here we report that HSF1 plays a role in the regulation of
cancer stem cell phenotype in breast cancer cell lines.
Previously, we demonstrated that high HSF1 expression is
associated with poor prognosis and increased mortality in
more than 1800 clinical breast cancer patients’ samples
[10]. In this study, we discovered that HSF1 is highly
expressed in breast CSC subpopulations. Furthermore, we
found that CSC phenotype is augmented by HSF1 over-
expression and inhibited by HSF1 knockdown in breast
cancer cells lines. Hence, cumulatively, our results suggest
that the correlation between high HSF1 expression and
poor patient outcome might be partially explained by the
actions of HSF1 on CSCs in breast tumor [29, 30, 33, 34].
Together these data suggest that HSF1-mediated aug-
mentation of CSC phenotype involves mechanisms in
addition to HSPs and EMT, including HSF1-mediated
protein translation that may be feature of CSC survival.
Interestingly, a recent genome-wide siRNA screen identi-
fied protein degradation and proteasome addiction as a
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Fig. 3 HSF1 confers drug resistance to breast cancer cells. a HSF1
over-expression increases resistance of cancer cell lines to paclitaxel
(Taxol) treatment. HSF1 over-expressionwas inducedwithDOX (1 ng/
ml) 2 days before drug treatment in SUM159 and BT20. The control
cells were treated with vehicle only (Ctrl) or with 2.5 nMTaxol (Taxol)
without HSF1 induction with DOX and compared to 2.5 nMTaxol plus
HSF1 over-expression (Taxol ? HSF1). Cell viability was calculated
using Trypan blue exclusion method after 4 days of treatment. The
bright field images provide a representative example (109 magnifica-
tion) and the bar graphs show that the reduction in cell numbers
observed with Taxol treatment (striped bars) is prevented with HSF1
over-expression (black bars), compared to control (white bars). Error
bars show standard deviation of the mean of 3 replicates (p\ 0.05).
b HSF1 knockdown increases cancer cell line sensitivity to taxol
treatment. HSF1 knockdown was induced with DOX (1 ng/ml) 2 days
before drug treatment in MCF7, BT474, and T47D that were treated
with vehicle only (Ctrl), 2.5 nM Taxol (Taxol) and 2.5 nM Taxol plus
HSF1 knockdown (Taxol ? HSF1-KD). Cell viability was calculated
using Trypan blue exclusion method after 4 days of treatment. The
bright field images provide a representative example (109 magnifica-
tion) and the bar graphs show that the reduction in cell numbers
observed with Taxol treatment (striped bars) is enhanced with HSF1
knockdown (black bars), compared to control (white bars). Error bars
show standard deviation of the mean of 3 replicates (p\ 0.05). cHSF1
over-expression increases the number of CSCs in breast cancer cell
lines treated with taxol. SUM159 cell line expressing inducible HSF1
was plated into T25 flasks with or without DOX (Ctrl or HSF1) for
2 days. Next, the cells were treated with 5 nM taxol for 4 days and
allowed to recover in freshmedia for 3 days before tumorsphere assays.
Tumorsphere formation was carried out by seeding 1 9 104 cells into
6-well low adherent plates. The number of spheres was counted after
10–14 days. Tumorsphere formation efficiency (TFE) was compared
between control (Ctrl, vehicle only), Taxol treated (Taxol), and Taxol
treated plus HSF1 over-expression (Taxol ? HSF1). The bright field
images provide a representative example and the bar graphs show that
the reduction in sphere numbers observedwith Taxol treatment (striped
bars) which is prevented with HSF1 over-expression (black bars),
compared to control (white bars).Error bars show standard deviation of
the mean of 3 replicates (p\ 0.05). d HSF1 knockdown inhibits CSCs
in breast cancer cells lines treated with taxol. Inducible HSF1
knockdown in BT474 cells was induced by adding DOX for 2 days.
Cells were then treated with 5 nM for 4 days. After 3 days of recovery
in drug-free medium, tumorsphere formation was carried out as
described above and compared between control (Ctrl, vehicle only),
taxol treated (Taxol), and Taxol treated plus HSF1 knockdown (Taxol/
HSF1 KD) groups. The bright field images provide a representative
example and the bar graphs show that the reduction in cell numbers
observed with Taxol treatment (striped bars), which is enhanced with
HSF1 knockdown (black bars), compared to control (white bars).Error
bars show standard deviation of the mean of 3 replicates (p\ 0.05).
Insets: tumorsphere formation image taken at 49 magnification under
bright light field with inverted microscopy
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vulnerability of HSF1high CSC-like BPLER cells, which
provides independent corroboration of these results [21].
The inhibition of the proteasome reduced growth of
established breast cancers in mice and blocked tumor ini-
tiation by CSCs and metastasis [21]. It is intriguing that the
hypothesis-based studies converge with unbiased high-
throughput screens over the protein turn-over machinery.
While the role of HSF1 has been traditionally explored
in terms of its role in regulating HSPs and stress response,
there is rapidly growing evidence that HSF1 regulates
many non-HSPs genes that regulate many cellular pro-
cesses including protein translation, cell cycle, glucose
anabolic metabolism, autophagy, apoptosis, p53, Ras,
MAPK, cAMP, PKA, and mTOR pathways [11, 35–37].
Our results suggest that some of these non-HSP targets of
HSF1 may be involved in the regulation of CSC phenotype
as well, which makes HSF1 as a potential target to develop
CSC-specific therapies [32, 38–40].
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Fig. 4 Mechanisms of CSC regulation by HSF1 a Western blots of
three matched pairs of HSF1high CSC-like BPLER vs. HSF1low non-
CSC-like HMLER cells (#2-4) reveal only minor differences in heat
shock proteins HSP70 and HSP90. The cell lysates were probed with
anti-HSP70 and anti-HSP90 antibodies. b-actin (Actin) was used as
loading control. b Real-time PCR analysis of ZEB1 mRNA reveals no
significant change with HSF1 over-expression (left panel) and
knockdown (right panel) after 2 days DOX addition. The Zeb1
mRNA was quantified with real-time PCR after HSF1 over-expres-
sion in SUM159 and BT20 cells (black bar, left panel) or knockdown
in BT474, T47D, and MCF7 cells (black bar, right panel) compared
to control cells without DOX (white bars). GAPDH was used to
normalize Ct value. The error bars represent standard deviation of the
mean. c HSF1 over-expression or knockdown has no effect on heat
shock protein (HSP) or EMT marker expression. Western blot
analysis of HSF1, HSP 70, 90, E-cadherin(E-cad), and Vimentin(-
Vim) after HSF1 over-expression (HSF1) in SUM159 and BT20 cells
(left panel) and knockdown (KD) in BT474, T47D, and MCF7 cells
(right panel) cells compared to control cells (without DOX) revealed
no significant changes. b-actin (Actin) was used as loading control.
d HSF1high CSC-like BPLER cells are more sensitive to protein
translation inhibition compared to HSF1low non-CSC-like HMLER
cells. Three pairs of matched BPLER and HMLER cell lines (#2–4)
were treated either with cycloheximide (top panel) or anisomycin
(bottom panel) for 8 h, and cultured in drug-free medium for 4 days
and cell viability was measured with celltiter-blue assay on day 4. The
bar graphs show percent cell viability as compared to control cells
(100 %, not shown here). HMLER: white bar; BPLER: black bar
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